Analysis of miR-145 expression levels in 86 primary diagnostic neuroblastoma samples revealed significantly lower expression of miR-145 (based on median expression) in patients with known higher risk prognostic factors including MYCN amplification (MNA) [23] and INSS Stage 4 disease [24] (Figure 1(a)). The gene discussed is MYCN; the disease is neuroblastoma.